1. HBW Insight
  2. >>Ingredients & Safety

CIR Tables Review Of Preservative PHMB; Industry Maintains Data Is On The Way

 
• By Eileen Francis

The Cosmetic Ingredient Review Expert Panel tabled a draft final report for preservative polyaminopropyl biguanide June 5 to await promised sensitization and exposure data from industry. There is concern that an “insufficient data” decision could prompt reformulations with even more questionable alternatives in a market short on preservative options.

waiting for the artist

Concerns about the prospect of questionable reformulations led the Cosmetic Ingredient Review Expert Panel to table a draft final report on preservative polyaminopropyl biguanide (PHMB) June 5, rather than tagging it with an “insufficient data” conclusion.

The move came after lengthy deliberation, with disagreement between the panel’s two teams, led by James Marks, dermatology professor at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

Review Suggests Advantage Of Bayer’s Iberogast Advance For Digestive Disorders

 
• By David Ridley

Bayer's Iberogast Advance's combination of six herbal ingredients may produce a synergistic effect that acts on multiple underlying issues contributing to digestive disorders like functional dyspepsia (FD) and irritable bowel syndrome (IBS), a recently published study suggests.

Allergy Ingredient Itch Warning, ACNU Final Rule Scratch Extent Of FDA Authority For Label Changes

 
• By Malcolm Spicer

Effective date for ACNU OTC switch final rule and finding of severe itching from long-term use of common allergy ingredients are bookends for limits of FDA’s authority for product label changes.

More from HBW Insight

‘Off-Label’ Beauty Hacks: Navigating the Risks of Consumer-Driven Innovation

 
• By Rachel Raphael, Elizabeth Bresnahan and Kathryn Ignash

Guest authors Rachel Raphael, partner at Morgan, Lewis & Bockius, LLP and associates at the firm, Elizabeth Bresnahan and Kathryn Ignash, advise beauty companies on how to navigate the legal risks associated with consumers ‘off-label’ beauty hacks.

Danone Acquires Belgian Firm Marketing Gut Health Supplement in US

 
• By Tom Gallen

Danone moves into dietary supplements space with deal for The Akkermansia Company marketing patented biotic strain in US, Europe and Asia.

US Adverse Event Report Forms Replace ‘Gender’ Options With Male Or Female ‘Sex’ Question

Modifications to forms FDA 3500, for voluntary reporting by healthcare professionals, and 3500A, for mandatory reporting by manufacturers, marketers or facilities, include limiting changing gender question to sex and asking for only male or female answer.